David Slovick was quoted in a Clinical Trials Arena article, “Cassava Sciences: Phase III Trials Storm Ahead Amid Controversy,” regarding recent charges filed by the Securities and Exchange Commission related to misleading statements made in September 2020 by Cassava Sciences.
